Quick Answer
10x Genomics, Inc. reported Net Income Loss of -$43.54 million for the year ending 2025.
- 10x Genomics, Inc. showed an increase of +76.2% in Net Income Loss from 2024 to 2025.
- This data is from 10x Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$15.69 million | Q2 2018: -$5.92 million | Q3 2018: -$15.35 million | Q4 2018: -$75.52 million | Q1 2019: -$3.64 million | Q2 2019: -$10.88 million | Q3 2019: -$9.60 million | Q4 2019: -$7.13 million | Q1 2020: -$21.14 million | Q2 2020: -$40.17 million | Q3 2020: -$65.85 million | Q1 2021: -$11.55 million | Q2 2021: -$11.05 million | Q3 2021: -$17.17 million | Q1 2022: -$42.41 million | Q2 2022: -$64.46 million | Q3 2022: -$41.91 million | Q1 2023: -$50.75 million | Q2 2023: -$62.41 million | Q3 2023: -$92.99 million | Q1 2024: -$59.95 million | Q2 2024: -$37.90 million | Q3 2024: -$35.75 million | Q1 2025: -$34.36 million | Q2 2025: $34.54 million | Q3 2025: -$27.47 million.
- Over the full 9 years of available data (2017 to 2025), 10x Genomics, Inc.'s Net Income Loss has declined by 132.1%.
- Historical annual values: Fiscal year 2025: -$43.54 million | Fiscal year 2024: -$182.63 million | Fiscal year 2023: -$255.10 million | Fiscal year 2022: -$166.00 million | Fiscal year 2021: -$58.22 million | Fiscal year 2020: -$542.73 million | Fiscal year 2019: -$31.25 million | Fiscal year 2018: -$112.49 million | Fiscal year 2017: -$18.76 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: